N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-2-nitrobenzenesulfenamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-2-nitrobenzenesulfenamide
• 英文别名: 4-(5-chloropyrimidin-2-yl)oxy-3-methyl-N-(2-nitrophenyl)sulfanylaniline
• 化学式: C₁₇H₁₃ClN₄O₃S
• 分子量: 388.834
• InChiKey: LDUBJZHIDJWMSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-nitrobenzoyl isocyanate 、 N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-2-nitrobenzenesulfenamide 以 1,2-二氯乙烷 为溶剂， 反应 1.5h， 生成 N-[[4-(5-chloropyrimidin-2-yl)oxy-3-methylphenyl]-(2-nitrophenyl)sulfanylcarbamoyl]-2-nitrobenzamide
  参考文献：
  名称：

  苯甲酰基苯基脲的前药的合成及其抗肿瘤活性。

  摘要：

  合成了各种苯甲酰基苯基脲衍生物作为候选前药，并在体内检查了它们对P388白血病的抗肿瘤活性。所有的前药都可溶于大多数有机溶剂，并且在腹膜内或口服时对小鼠的P388白血病细胞显示出良好的抗肿瘤活性。

  DOI：

  10.1248/cpb.42.57
• 作为产物：
  描述：

  2-硝基苯硫氯 、 4-((5-chloropyrimidin-2-yl)oxy)-3-methylaniline 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-2-nitrobenzenesulfenamide
  参考文献：
  名称：

  苯甲酰基苯基脲的前药的合成及其抗肿瘤活性。

  摘要：

  合成了各种苯甲酰基苯基脲衍生物作为候选前药，并在体内检查了它们对P388白血病的抗肿瘤活性。所有的前药都可溶于大多数有机溶剂，并且在腹膜内或口服时对小鼠的P388白血病细胞显示出良好的抗肿瘤活性。

  DOI：

  10.1248/cpb.42.57

文献信息

• Substituted benzene derivatives, processes for their production and
  申请人：Ishihara Sangyo Kaisha Ltd.

  公开号：US04987135A1

  公开（公告）日：1991-01-22

  A substituted benzene derivative represented by a formula: ##STR1## where A represents: ##STR2## wherein X is a hydrogen atom, a halogen atom or a nitro group, R.sup.1 is --X.sup.1 Z.sup.1 (X.sup.1 is an oxygen atom or a sulfur atom and Z.sup.1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group), --COZ.sup.1 group (Z.sup.1 is as defined above), ##STR3## group (Z.sup.1 is as defined above, Z.sup.2 is --CO.sub.2 Z.sup.3 wherein Z.sup.3 is the same as Z.sup.1, or --SO.sub.2 Z.sup.3 wherein Z.sup.3 is as defined above and n is 0 or 1), ##STR4## (Z.sup.1 and Z.sup.3 are as defined above) or ##STR5## (X.sup.2, X.sup.3 and X.sup.4 are, respectively, an oxygen atom or a sulfur atom and Z.sup.4 and Z.sup.5 are the same as Z.sup.1), and R.sup.3 is a nitro group or ##STR6## (R.sup.4 and R.sup.5 are, respectively, an alkyl group, or they may form a heterocyclic group together with the adjacent nitrogen atom), or ##STR7## wherein X and R.sup.3 are as defined above and R.sup.2 is --X.sup.1 Z.sup.1 (X.sup.1 and Z.sup.1 are as defined above); Y is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group, a nitro group or ##STR8## (R.sup.6 and R.sup.7 are, respectively, a substituted or unsubstituted alkyl group); R is ##STR9## (R.sup.8 is the same as Y and q is an integer of 1 to 4), ##STR10## (R.sup.8 is as defined above, and r is an integer of 1 to 3) or ##STR11## (R.sup.8 and r are defined above); and m is an integer, of 1 to 4, or its salt.

  一个以下式表示的取代苯衍生物：其中A代表：其中X是氢原子、卤原子或硝基基团，R.sup.1是--X.sup.1 Z.sup.1（X.sup.1是氧原子或硫原子，Z.sup.1是取代或未取代的烷基基团、取代或未取代的烯基基团、取代或未取代的炔基基团、取代或未取代的芳基基团或取代或未取代的杂芳基团）、--COZ.sup.1基团（Z.sup.1如上定义），##STR3##基团（Z.sup.1如上定义，Z.sup.2是--CO.sub.2 Z.sup.3，其中Z.sup.3与Z.sup.1相同，或--SO.sub.2 Z.sup.3，其中Z.sup.3如上定义，n为0或1），##STR4##（Z.sup.1和Z.sup.3如上定义）或##STR5##（X.sup.2、X.sup.3和X.sup.4分别为氧原子或硫原子，Z.sup.4和Z.sup.5与Z.sup.1相同），R.sup.3是硝基基团或##STR6##（R.sup.4和R.sup.5分别为烷基基团，或它们与相邻氮原子一起形成杂环基团），或##STR7##其中X和R.sup.3如上定义，R.sup.2是--X.sup.1 Z.sup.1（X.sup.1和Z.sup.1如上定义）；Y是卤原子、取代或未取代的烷基基团、取代或未取代的烷氧基团、取代或未取代的烷硫基团、硝基或##STR8##（R.sup.6和R.sup.7分别为取代或未取代的烷基基团）；R是##STR9##（R.sup.8与Y相同，q为1至4的整数），##STR10##（R.sup.8如上定义，r为1至3的整数）或##STR11##（R.sup.8和r如上定义）；m为1至4的整数，或其盐。
• Substituted benzene derivatives, processes for their production and antitumour compositions containing them
  申请人：ISHIHARA SANGYO KAISHA, LTD.

  公开号：EP0335408A2

  公开（公告）日：1989-10-04

  A substituted benzene derivative represented by a formula: where A represents: wherein X is a hydrogen atom, a halogen atom or a nitro group, R¹ is -X¹Z¹ (X¹ is an oxygen atom or a sulfur atom and Z¹ is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substitute or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group), -COZ¹ group (Z¹ is as defined above), group (Z¹ is as defined above, Z² is -CO₂Z³ wherein Z³ is the same as Z¹, or -SO₂Z³ wherein Z³ is as defined above and n is 0 or 1), (Z¹ and Z³ are as defined above) or (X², X³ and X⁴ are, respectively, an oxygen atom or a sulfur atom and Z⁴ and Z⁵ are the same as Z¹), and R³ is a nitro group or (R⁴ and R⁵ are, respectively, an alkyl group, or they may form a heterocyclic group together with the adjacent nitrogen atom), or wherein X and R³ are as defined above and R² is -X¹Z¹ (X¹ and Z¹ are as defined above); Y is a halogen atom, a subsituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkythio group, a nitro group or (R⁶ and R⁷ are, respectively, a substituted or unsubstituted alkyl group); R is (R⁸ is the same as Y and q is an integer of 1 to 4), (R⁸ is as defined above, and r is an integer of 1 to 3) or (R⁸ and r are as defined above); and m is an integer of 1 to 4, or its salt.

  一种取代的苯衍生物，由式表示： 其中 A 代表 其中 X 是氢原子、卤素原子或硝基，R¹ 是-X¹Z¹（X¹ 是氧原子或硫原子，Z¹ 是取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的芳基或取代或未取代的杂芳基），-COZ¹ 基团（Z¹ 如上定义）、 基团（Z¹ 如上定义，Z² 为-CO₂Z³，其中 Z³ 与 Z¹ 相同，或-SO₂Z³，其中 Z³ 如上定义，且 n 为 0 或 1）、 (Z¹ 和 Z³ 如上定义）或 (X²、X³ 和 X⁴ 分别为氧原子或硫原子，且 Z⁴ 和 Z⁵ 与 Z¹ 相同），且 R³ 为硝基或 (R⁴ 和 R⁵ 分别为烷基，或可与相邻的氮原子一起形成杂环基团），或 其中 X 和 R³ 如上文所定义，R² 是-X¹Z¹（X¹ 和 Z¹ 如上文所定义）；Y 是卤素原子、取代或未取代的烷基、取代或未取代的烷氧基、取代或未取代的烷硫基、硝基，或 (R⁶ 和 R⁷ 分别是取代或未取代的烷基）； R 是 (R⁸ 与 Y 相同，q 为 1 至 4 的整数)、 (R⁸如上定义，且 r 为 1 至 3 的整数）或 (R⁸ 和 r 如上定义）；以及 m 是 1 至 4 的整数，或其盐。
• US4987135A
  申请人：——

  公开号：US4987135A

  公开（公告）日：1991-01-22
• Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas.
  作者：Hiroshi OKADA、Tohru KOYANAGI、Nobutoshi YAMADA

  DOI：10.1248/cpb.42.57

  日期：——

  Various benzoylphenylurea derivatives were synthesized as candidate prodrugs and their antitumor activities were examined in vivo against P388 leukemia. All of the prodrugs were soluble in most organic solvents and showed good antitumor activities against P388 leukemia cells in mice when dosed intraperitoneally or orally.

  合成了各种苯甲酰基苯基脲衍生物作为候选前药，并在体内检查了它们对P388白血病的抗肿瘤活性。所有的前药都可溶于大多数有机溶剂，并且在腹膜内或口服时对小鼠的P388白血病细胞显示出良好的抗肿瘤活性。